Immuno-inflammatory signature for predicting therapeutic response and survival after stereotactic radiosurgery in NSCLC patients with brain metastases: a retrospective cohort study

免疫炎症特征预测非小细胞肺癌脑转移患者立体定向放射外科治疗反应和生存期:一项回顾性队列研究

阅读:1

Abstract

PURPOSE: This study aimed to delineate critical factors, particularly immune-inflammatory biomarkers, that predict therapeutic response and overall survival (OS) in non-small cell lung cancer (NSCLC) patients with brain metastases (BM) undergoing stereotactic radiosurgery (SRS), and to develop novel decision-tree and nomogram models for prognostication. PATIENTS AND METHODS: In this retrospective study, we analyzed data from 464 NSCLC patients with BM treated with SRS between February 2016 and November 2022. The cohort was randomly split into training and validation sets (7:3 ratio). A C5.0 algorithm was employed to build a decision tree model for treatment response. Prognostic factors for OS were identified via univariate and multivariate Cox regression, and subsequently used to construct graphical and online nomograms. Model performance was assessed with calibration curves and the C-index. RESULTS: The median OS for the entire cohort was 15.8 months (95% confidence interval [CI]: 14.6 to 17.0 months). The decision tree model for treatment response identified NLR as a key predictor, alongside volume of brain metastases, Score Index for Radiosurgery (SIR), edema index (EI), and maximum diameter. Multivariate Cox analysis identified age, volume of brain metastases, EI, and SIR as independent prognostic factors for OS. Graphical and dynamic nomograms were developed based on these factors (available at: https://helloshinyweb.shinyapps.io/brain_metastasis_from_NSCLC/). The calibration curves demonstrated good consistency between predicted and actual survival, and the C-index indicated a moderate discriminative ability. CONCLUSIONS: We identified that immune-inflammatory profiles and radiological-clinical factors are significant predictors for treatment response and OS in NSCLC patients with BM undergoing SRS. The developed decision tree and nomogram models, which incorporate immune-inflammatory profiles, provide user-friendly tools to assist clinicians in optimizing personalized management for this patient population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。